Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term

Company Overview - Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel, involved in the development, manufacturing, and marketing of both branded and generic drugs, including biosimilars and over-the-counter products, as well as active pharmaceutical ingredients (APIs) [12] - Teva's generic product portfolio includes various forms such as tablets, capsules, liquids, ointments, creams, transdermal patches, injectables, and inhalants [12] - The company plans to separate its API unit into a standalone business unit through a sale [12] Investment Ratings - Teva is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of B, indicating a solid position in the market [13] - The Value Style Score for Teva is also B, supported by attractive valuation metrics, including a forward P/E ratio of 10.22, which may appeal to value investors [13] Earnings Estimates - In the last 60 days, five analysts have revised their earnings estimates upwards for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.07 to $2.61 per share [13] - Teva has demonstrated an average earnings surprise of +7.9%, indicating a positive trend in earnings performance [13] Investment Consideration - With a solid Zacks Rank and favorable Value and VGM Style Scores, Teva is recommended to be on investors' short lists for potential investment opportunities [14]